secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001628280-23-033014
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology reports positive Phase 2 data for onvansertib in pancreatic and lung cancers
--------------------------------------------------------------------------------

- mPDAC Phase 2: ORR 19% (1 confirmed PR, 3 pending) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo.
- Biomarker trial: single-agent onvansertib reduced Ki67 by 86% and CA19-9 by 28% in refractory mPDAC.
- Plans first-line mPDAC investigator-initiated trial of onvansertib + Gemzar/Abraxane at OHSU.
- SCLC Phase 2: preliminary single-agent activity; safety confirmed; trial continues enrolling.
- Conference call scheduled for Sept 26, 2023 at 5pm ET to discuss data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023033014/0001628280-23-033014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023033014/crdf-20230926.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-033014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer